论文部分内容阅读
目的:测定膀胱癌患者血浆中纤溶酶原激活物抑制剂1(Plasminogen activator inhibitor-1,PAI-1)浓度变化情况,探讨PAI-1浓度在膀胱癌诊断中的作用。方法:收集膀胱癌血液标本52例,并以正常人血液标本作对照,用ELISA法检测膀胱癌患者及正常对照组血浆中PAl-1的含量,并比较其差异。结果:膀胱癌患者血浆中PA1-1含量(22.49±9.54 ng/ml)明显高于对照组(P<0.01)。PAI-1浓度在膀胱癌Ⅳ期的含量与Ⅰ、Ⅱ、Ⅲ期比均有不同程度升高(P<0.05)。结论:血浆中PAI-1的浓度升高可作为膀胱癌诊断辅助指标,也可作为膀胱癌预后指标。
Objective: To determine the changes of plasminogen activator inhibitor-1 (PAI-1) in plasma of patients with bladder cancer and to explore the role of PAI-1 in the diagnosis of bladder cancer. Methods: Blood samples of bladder cancer were collected from 52 cases. The blood samples of normal people were used as control. The plasma levels of PAI-1 in bladder cancer patients and normal control group were detected by ELISA. The differences were compared. Results: The plasma levels of PA1-1 in bladder cancer patients (22.49 ± 9.54 ng / ml) were significantly higher than those in controls (P <0.01). The content of PAI-1 in stage Ⅳ of bladder cancer was significantly higher than that in stage Ⅰ, Ⅱ and Ⅲ (P <0.05). Conclusion: The increase of PAI-1 in plasma can be used as an auxiliary index in the diagnosis of bladder cancer and also as a prognostic indicator of bladder cancer.